Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
Interleukin-2 (IL-2) was initially discovered and used as a stimulator of effector T
lymphocytes (Teffs), but is now viewed as a very promising immunoregulatory drug having the
capacity to stimulate regulatory T cells (Tregs). At low dose, Il-2 tips the Treg/Teff
balance towards Tregs. Recently, it has been shown that Tregs of MS patients have reduced
proliferative potential. MS-IL2 will assess the safety and biological efficacy of low-dose
IL2 as a Treg inducer in a Relapsing-Remitting Multiple Sclerosis (RRMS), with the aim to
stimulate Treg and define potential clinical benefits